NADIA YOUNUS: Open Payments
NPI 1942573340 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,468 in 56 payments from 20 companies in 2025. Trend: 2023 $1,765 · 2024 $1,630 · 2025 $1,468
Food & beverage: $1,468
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $278 |
| CeQur Corporation | 1 | $230 |
| Ascensia Diabetes Care Us Inc. | 6 | $151 |
| BETA BIONICS, INC. | 5 | $110 |
| Corcept Therapeutics | 5 | $94 |
| Amgen Inc. | 4 | $84 |
| Astellas Pharma US Inc | 3 | $75 |
| Novartis Pharmaceuticals Corporation | 3 | $75 |
| Mannkind Corporation | 3 | $56 |
| Amphastar Pharmaceuticals, Inc. | 2 | $43 |
Products named: CeQur Simplicity, Ozempic, Rybelsus, iLet Bionic Pancreas, Korlym, Veozah, LEQVIO, REPATHA.
Industry payments across TX — which companies pay providers there.
